Medical Terminology


« Back to Glossary Index

Solriamfetol (Sunosi) is a non-stimulant wake-promoting medication that was approved in March 2019 by the U.S. FDA for the treatment of sleepiness caused by narcolepsy and obstructive sleep apnea. It is the first dual-acting dopamine and norepinephrine reuptake inhibitor (NDRI) approved to treat excessive daytime sleepiness in adults. Read more about solriamfetol at HERE and on HF’s Treatment web page HERE.


The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.